

## Karoline Lerang

---

Date of birth: 12.07.1972  
 E-mail address: klerang@ous-hf.no  
 Contact details: Karoline Lerang  
 Department of Rheumatology  
 Oslo University Hospital- NORWAY  
 Postboks 4959 Nydalen  
 0424 Oslo

### Current position(s):

From year	Position	% employment	Name of institution
2022-	Chief physician and senior researcher	50/50%	Department of Rheumatology, Oslo University Hospital, Norway

### Previous positions:

Year		Position held	Name of institution
From	To		
2018	2022	Chief physician and Post doc 50/50%	Department of Rheumatology, Oslo University Hospital, Norway
2017	2018	Post doc	Department of Rheumatology, Oslo University Hospital, Norway
2015	2016	Chief physician	Department of Rheumatology, Oslo University Hospital, Norway
04.2015	08.2015	Assistant physician	Section for Pediatric Rheumatology, Oslo University Hospital, Norway
2013	2015	Assistant physician (rotation),	Department of Rheumatology, Diakonhjemmet Hospital, Norway
2011	2013	Assistant physician	Department of Rheumatology, Oslo University Hospital, Norway
2006	2006	Assistant physician	Department of Rheumatology, Oslo University Hospital, Norway
2003	2005	Assistant physician	Devision of Medicine, Oslo University Hospital, Norway
2002	2003	Assistant physician	Devision om Medicine, Stavanger University Hospital, Norway
2000	2002	Internship	Haugesund Hospital, Norway

### Education:

Year	Academic degree	Name of institution
2015	Ph.D (dr. med)	University of Oslo (UiO)
2015	Specialist in Rheumatology	Norwegian medical association

2000	Cand med	University of Bergen (UiB)
------	----------	----------------------------

**Additional information:** Mother to two children born in 2005 and 2007

#### Relevant teaching:

Year	Teaching activity	Name of Institution
2012–15	Member of the teaching committee for assistant physicians in Rheumatology	Oslo University Hospital
2015–	Developed, managing and teaching at courses for SLE and Sjogrens patients	*Laering og mestringssenteret*, Rikshospital, OUS
2020-	Member of National guidelines for SLE	Norwegian society for rheumatology
2023-	Book chapter on SLE	Book; "Revmatologi"

#### Main supervisor of PhD students:

Year	Name of PhD student	Title of the thesis
2019–	Hilde Haukeland	How dangerous is SLE in a woman's health perspective A population based study
2020–	Sigrid Reppe Moe	Drug prescription before and after disease onset in a population based systemic lupus erythematosus patient cohort; - a controlled study from the Norwegian Prescription database

#### Co-supervisor of PhD students

2024-		Revolutionizing lupus nephritis diagnosis: A multi-center Scandinavian study
-------	--	--

#### PI role in local research projects

2023-		Biomarker Development for Early Diagnosis of Lupus Nephritis Using Liquid Biopsy
-------	--	--

#### Fellowships

2017– Clinical post-doc stipend from the DAM foundation IF O 147 069 "Hvor farlig er SLE egentlig?", grants from «Norsk revmatikerforening» (NRF), Vivi Irene Hansens foundation, «Fondsstiftelsen»

#### Other relevant assignments:

##### Mid-term evaluation committee

Year	Name of PhD student	
2019	Håvard Fredtheim	Department of rheumatology, Oslo University Hospital
2021	Ingrid Egeland Christensen	Department of rheumatology, Oslo University Hospital

##### Leadership

2017- SLE research group, department for Rheumatology, Oslo University Hospital  
2017- Leader of SLE network, South-Eastern Norway Regional Health Authority

**Invited reviewer**

Reviewer for peer-reviewed journals such as Lupus, Lupus science and medicine, Scandinavian Journal of Rheumatology, Clinical Epidemiology, Journal of Women's Health, Arthritis care and Res.

**Role in clinical trials**

- 2020– PI in Study CAIN457Q12301 with tile of “A two year phase III randomized, double-blind, parallelgroup, placebo-controlled trial to evaluate the safety and efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with lupus nephritis”.
- 2015–2020 PI in Study 201842 with tile of “A randomized, double blind (sponsor open), comparative, multi-center study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab co-administration in subjects with primary Sjögren’s syndrome”.
- 2004–2005 LUNDBECK study 10413 with tittle of “A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms”

**Publications:**

1. Haukeland H, R Moe S, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås H, Bøe T, Orre A, Garen T, Molberg Ø, **Lerang K**. Declining incidence of systemic lupus erythematosus in Norway 1999–2017: - Data from a population cohort identified by ICD-10 code and verified by classification. *Arthritis Rheumatol*. 2023 Dec
2. Hedenstedt A, Reid S, Sayadi A, Eloranta ML, Skoglund E, Bolin K, Frodlund M, **Lerang K**, Jönsen A, Rantapää-Dahlqvist S, Bengtsson AA, Rudin A, Molberg Ø, Sjöwall C, Sandling JK, Leonard D. B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus. *Lupus Sci Med*. 2023 Oct;10(2):e000926. doi: 10.1136/lupus-2023-000926
3. Moe SR, Haukeland H, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås H, Bøe T, Orre A, Garen T, Lilleby V, Provan SA, Molberg Ø, **Lerang K**. Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999–2022. *Rheumatology (Oxford)*. 2023 Sep 28:kead519. doi: 10.1093/rheumatology/kead519. Online ahead of print.
4. Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, **Lerang K**, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. *JCI Insight*. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030.
5. Piga M, Chessa E, Morand EF, Ugarte-Gil MF, Tektonidou M, van Vollenhoven R, Petri M, Arnaud L; PISCOS Investigator Group. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. *Lancet Rheumatol*. 2022 Jun;4(6):e441-e449. doi: 10.1016/S2665-9913(22)00107-2. Epub 2022 May 4
6. Reppe Moe S, Haukeland H, Molberg Ø, **Lerang K**. Long-Term Outcome in Systemic Lupus Erythematosus; Knowledge from Population-Based Cohorts. *J Clin Med*. 2021 Sep 22;10(19):4306. doi: 10.3390/jcm10194306.

7. Reid, S., Hagberg, N., Sandling, J.K., Alexsson, A., Pucholt, P., Sjöwall, C., **Lerang, K.**, Jönsen, A., Gunnarsson, I., Syvänen, A.-C., Troldborg, A.M., Voss, A., Bengtsson, A.A., Molberg, Ø., Jacobsen, S., Svenungsson, E., Rönnblom, L., Leonard, D., Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus (2021) *Annals of the Rheumatic Diseases*, 80 (9), pp. 1183-1189. DOI: 10.1136/annrheumdis-2020-219727
8. Bolin, K., Imgenberg-Kreuz, J., Leonard, D., Sandling, J.K., Alexsson, A., Pucholt, P., Haarhaus, M.L., Almlöf, J.C., Nititham, J., Jönsen, A., Sjöwall, C., Bengtsson, A.A., Rantapää-Dahlqvist, S., Svenungsson, E., Gunnarsson, I., Syvänen, A.-C., **Lerang, K.**, Troldborg, A., Voss, A., Molberg, Ø., Jacobsen, S., Criswell, L., Rönnblom, L., Nordmark, G., Variants in BANK1 are associated with lupus nephritis of European ancestry (2021) *Genes and Immunity*, 22 (3), pp. 194-202. DOI: 10.1038/s41435-021-00142-8
9. Sandling, J.K., Pucholt, P., Hultin Rosenberg, L., Farias, F.H.G., Kozyrev, S.V., Eloranta, M.-L., Alexsson, A., Bianchi, M., Padyukov, L., Bengtsson, C., Jonsson, R., Omdal, R., Lie, B.A., Massarenti, L., Steffensen, R., Jakobsen, M.A., Lillevang, Sø.T., **Lerang, K.**, Molberg, Ø., Voss, A., Troldborg, A., Jacobsen, Sø., Syvänen, A.-C., Jönsen, A., Gunnarsson, I., Svenungsson, E., Rantapää-Dahlqvist, S., Bengtsson, A.A., Sjöwall, C., Leonard, D., Lindblad-Toh, K., Rönnblom, L., Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing (2021) *Annals of the Rheumatic Diseases*, 80 (1), pp. 109-117., DOI: 10.1136/annrheumdis-2020-218636
10. Reppe Moe, S.E., Molberg, Ø., Strøm, E.H., **Lerang, K.**, Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort (2019) *Lupus*, 28 (7), pp. 818-825., DOI: 10.1177/0961203319847275
11. Garen, T., **Lerang, K.**, Hoffmann-Vold, A.-M., Andersson, H., Midtvedt, Ø., Brunborg, C., Kilian, K., Gudbrandsson, B., Gunnarsson, R., Norby, G., Chaudhary, A., Thoen, J., Forseth, K.Ø., Fresjar, K., Førre, Ø., Haugen, M., Haga, H.-J., Gran, J.T., Gilboe, I.-M., Molberg, Ø., Palm, Ø., Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides (2019) *Rheumatology (United Kingdom)*, 58 (2), pp. 313-320., DOI: 10.1093/rheumatology/key285
12. **Lerang, K.**, Gilboe, I.-M., Steinar Thelle, D., Gran, J.T., Mortality and years of potential life loss in systemic lupus erythematosus: A population-based cohort study (2014) *Lupus*, 23 (14), pp. 1546-1552., DOI: 10.1177/0961203314551083
13. **Lerang, K.**, Gilboe, I., Garen, T., Thelle, D.S., Gran, J.T., High incidence and prevalence of systemic lupus erythematosus in Norway (2012) *Lupus*, 21 (12), pp. 1362-1369., DOI: 10.1177/0961203312458168
14. **Lerang, K.**, Gilboe, I., Gran, J.T., Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus (2012) *Rheumatology*, 51 (4), art. no. ker318, pp. 663-669., DOI: 10.1093/rheumatology/ker318
15. Norby, G.E., **Lerang, K.**, Holdaas, H., Gran, J.T., Strøm, E.H., Draganov, B., Os, I., Hartmann, A., Gilboe, I.-M., Lupusnefritt - diagnostikk og behandling (2010) *Tidsskrift for den Norske Laegeforening*, 130 (11), pp. 1140-1144., DOI: 10.4045/tidsskr.09.0583